期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

帕唑帕尼靶向治疗肾细胞癌的研究进展 被引量：2

Progress in targeted treatment of renal cell carcinoma with pazopanib
原文传递
导出
摘要 帕唑帕尼于2009年10月获美国FDA批准上市用于治疗肾细胞癌,是一种新型的口服多靶点酪氨酸激酶抑制剂。临床研究表明,其对肾细胞癌的药效明显、药动学稳定,安全性研究结果也表明患者耐受良好,该药为晚期肾细胞癌的治疗提供了新的选择。本文就肾细胞癌的发病机制、帕唑帕尼的临床研究和安全性研究及与其他治疗肾细胞癌的酪氨酸激酶抑制剂对比研究进行综述。 Pazopanib is a novel orally administered multi-targeted tyrosine kinase inhibitor （TKI） which was approved for the treatment of renal cell carcinoma by FDA in October 2009. Clinical researches have revealed that pazopanib not only has potent antitumor effect and good pharmacokinetics stability but also is well tolerated. It provided an alternative for the treatment of advanced renal cancer. This paper reviews the pathogenesis of renal carcinoma, clinical and safety research of pazopanib and contrast with other TKIs.
作者 常榕枝 钟俊 乌恩 王国成
机构地区 内蒙古医科大学 天津天士力集团研究院化学药物研究所
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2012年第10期569-574,共6页 Chinese Journal of New Drugs and Clinical Remedies
关键词 肾肿瘤 帕唑帕尼 药物疗法 靶向治疗 临床试验 kidney neoplasms pazopanib drug therapy targeted therapy clinical trials
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献17

  • 1JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics[J]. CA Cancer J Clin, 2009, 59(4): 225-249.
  • 2赵长林,殷洪霞.转移性肾癌分子靶向治疗进展[J].中国医师进修杂志（外科版）,2007,30(8):68-71. 被引量：1
  • 3KAELIN WG Jr. Molecular basis of the VHL hereditary cancer syndrome[J]. Nat Rev Cancer, 2002, 2(9) : 673-682.
  • 4MASSON N, WILLIAM C, MAXWELL PH, et ol. Independent function of two destruction domains in hypoxia inducible factor- alpha chains activated by prolyl hydroxylation[J]. EMBO J, 2001, 20(18) : 5197-5206.
  • 5RAMP U, REINECKE P, GABBERT HE, et al. Differential response to transforming growth factor (TGF)- alpha and fibroblast growth factor (FGF) in human renal cell carcinoma of the clear cell and papillary types[J]. Eur J Cancer, 2000, 36(7) : 932-941.
  • 6DVORAK HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy[J]. J Clin Oncol, 2002, 20(21 ) . 4368-4380.
  • 7COHEN HT, MCGOVERN FJ. Renal-cell carcinoma[J]. Nengl J Med, 2005, 353(23): 2477-2490.
  • 8HARRIS PA, BOLOOR A, CHEUNG M, et al. Discovery of 5- 114- [(2,3-dimethy1-2H -indazol-6-yl )methylamino] -2 -pyrimidinyl] amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor[J]. J Med Chem, 2008, 51(15): 4632-4640.
  • 9KUMAR R, KNICK VB, RUDOLPH SK, et aL Pharmaco- kinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity[J]. Mol Cancer Ther, 2007, 6(7) : 2012-2021.
  • 10COWEY CL, SONPAVDE G, HUTSON TE. New advancements and developnents in treatment of renal cell carcinoma: focus on pazopanib[J]. Onco Targets Ther, 2010, 3 : 147-155.

二级参考文献11

  • 1Gerald HM. Salvage surgery for advanced renal cell carcinoma [J]. Eur Urol Supp, 2004,3(3):2-8.
  • 2Drachenberg D, Childs RW. Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement [J]. Urol Clin North Am, 2003, 30(3) :611-622.
  • 3Paul R. Renal cell carcinoma.. Presentation, staging, and surgical treatment [J]. Semin Oncol, 2000, 27(2) : 160-176.
  • 4McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer [J]. Expert Opin Biol Ther, 2004, 4(4) : 455-468.
  • 5Leung SK, Ohh M. Playing tag with HIF: the VHL story [J]. J Biomed Biotechnol, 2002, 2(3) : 131-135.
  • 6Lane BR, Rini BI, Novick AC, et al. Targeted molecular therapy for renal cell carcinoma [J]. Urology, 2007, 69(1):3-10.
  • 7Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma [J]. Cancer, 2005, 104(11) :2323-2333.
  • 8Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor [J]. Curt Oncol Rep, 2007, 9(2):115- 119.
  • 9Hutson TE, Sonpavde G, Galsky MD. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials [J]. Clin Genitourin Cancer, 2006, 5 (suppl 1) :531-539.
  • 10Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma [J]. J Clin Oncol, 2006, 24(35):5601-5608.

共引文献5

同被引文献31

  • 1王松青,孙厚娥.企业实施专利战略刍议[J].沧桑,2007,0(5):108-108. 被引量：1
  • 2陈向东,张晨.在华制药领域专利技术资源竞争——美国制药企业专利资源竞争比较及其启示[J].中国软科学,2006(5):63-72. 被引量：17
  • 3GROSS- GOUPIL M, MASSARD C, RAVAUD A. Targeted therapies in metastatic renal cell carcinoma: overview of the past year[J]. Curr Urol Rep, 2012, 13(1): 16-23.
  • 4CARMICHAEL C, LAU C, JOSEPHSON DY, et al. Compre- hensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma[J]. Clin Adv Hematol Oncol, 2012, 10(5) : 307-314.
  • 5POSADAS EM, FIGLIN RA. Systemic therapy in renal cell carcinoma : advancing paradigms[J]. Oncology (Williston Park), 2012, 26(3): 290-301.
  • 6CHO IC, CHUNG J. Currrent status of targeted therapy for advanced renal cell carcinoma[J]. Korean J Urol, 2012, 23 (4): 217-228.
  • 7ESCUDIER B, GORE M. Axitinib for the management of metastatic renal cell carcinoma[J]. Drugs R D, 2011 (2): 113- 126.
  • 8RUGO HS, HERBST RS, LIA G, et ol. Phase I trial of the oral antiagiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results[J]. J Clin Oncol, 2005, 23(24): 5457-5483.
  • 9HO TH, JONASCH E. Axitinib in the treatment of metastatic renal cell carcinoma[J]. Future Oncol, 2011, 7 ( 11 ) : 1247-1253.
  • 10RIXE O, BUKOWSKI RM, MICHAELSON MD, et ol. Axitinib treatment in patients with eytokine- refractory metastatic renal- cell cancer: a phase lI study[J]. Lancet Oncol, 2007, 8 (1): 975-984.

引证文献2

二级引证文献5

中国新药与临床杂志
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部